Entrada Therapeutics, Inc.

TRDANASDAQHealthcare● Active

$6.26

$-0.11(-1.73%)

Market Cap$243017056

P/E Ratio—

52W High$16.45

52W Low$4.93

Avg Volume365K

Open$6.38

Beta-0.26

Net Income Financials Revenue

Entrada Therapeutics, Inc. (TRDA) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

TRDA · net income · updated Jun 9, 2026

Core profitability metrics

TRDA · net income · margin · TTM · CAGR

Net income was −$143.8M for FY2025 (fiscal year ending 2025-12-31), down 319.0% year-over-year. Net profit margin was -565.5%. Based on available data, Entrada Therapeutics, Inc. has been profitable since at least 2024.

FY2025 Net Income−$143.8M▼ -319.0% YoY

Trailing 12M (TTM)−$166.1Mtrailing 4 quarters sum

Net Profit Margin-565.5%−$143.8M ÷ $25.4M

YoY Change-319.0%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2024

▸ FMP /income-statement · Annual · TRDA net income history · TRDA profit margin

Annual net income data

TRDA · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$143.8M▼ 319.0%-565.5%$25.4M

FY2024★ First Profit$65.6M▲ +1081.7%31.1%$210.8M

FY2023Loss−$6.7M▲ +92.9%-5.2%$129.0M

FY2022Loss−$94.6M▼ 84.9%—$0

FY2021Loss−$51.2M▼ 92.9%—$0

Net income vs peers (Healthcare)

TRDA vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Entrada Therapeutics, Inc.YOU

TRDA

−$143.8M-319.0%-565.5%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Entrada Therapeutics, Inc. (TRDA) reported net income of −$143.8M for FY2025 (fiscal year ending 2025-12-31), down 319.0% year-over-year. The net profit margin was -565.5% — meaning the company kept $-5.65 of every dollar of revenue as profit.

Based on available data, Entrada Therapeutics, Inc. has been profitable since at least 2024. Net income reached a peak of $65.6M in FY2024. Data available for 7 fiscal years.

Entrada Therapeutics, Inc.'s net profit margin was -565.5% for FY2025, based on the latest annual results.

Investors sometimes search for "Entrada Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from TRDA net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

TRDA net income · 4 questions

Entrada Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $143.8M for FY2025.

is TRDA profitabledoes TRDA make a profitTRDA profitabilityTRDA profitable company

▸ Source: FMP /income-statement · GAAP · Entrada Therapeutics, Inc. · Entrada Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026